Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coeliac Disease Clear all
Completed Not applicable Interventional

Evaluation of Injection Techniques in Celiac Plexus Neurolysis

NCT02068677
View directory record Official record
Conditions
Pancreatic Cancer, Pain
Interventions
Sympathetic response, no sympathetic response
Other
Lead sponsor
AdventHealth
Other
Eligibility
19 Years to 89 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 30, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional

A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease

NCT07377565
View directory record Official record
Conditions
Celiac Disease
Interventions
HB-2121
Drug
Lead sponsor
Nielsen Fernandez-Becker
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes

NCT01932476
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Gluten Challenge, Sham Challenge
Dietary Supplement
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 30, 2026, 4:14 AM EDT
Withdrawn Phase 1 Interventional

A Study of Guselkumab in Adult Participants With Celiac Disease

NCT04704843
View directory record Official record
Conditions
Celiac Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Lancaster, California • Chesterfield, Michigan • Wyoming, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Terminated No phase listed Observational

Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting

NCT02036944
View directory record Official record
Conditions
Celiac Disease, Iron Deficiency, Iron Malabsorption
Interventions
Not listed
Lead sponsor
Providence Medical Research Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

NCT05636293
View directory record Official record
Conditions
Celiac Disease
Interventions
Ritlecitinib, Placebo, Gluten
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease

NCT01137955
View directory record Official record
Conditions
Celiac Disease
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)

NCT03183609
View directory record Official record
Conditions
Schizophrenia, Gluten Sensitivity, Schizo Affective Disorder
Interventions
Gluten Flour in Protein Shake, Rice Flour in Protein Shake
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

PTG-100 for Patients With Celiac Disease

NCT04524221
View directory record Official record
Conditions
Celiac Disease
Interventions
PTG-100, Placebo
Drug
Lead sponsor
Nielsen Fernandez-Becker
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Results available

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

NCT03486990
View directory record Official record
Conditions
Celiac Disease
Interventions
TIMP-GLIA
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Sep 30, 2026, 4:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Celiac Ganglia

NCT01010360
View directory record Official record
Conditions
Celiac Ganglia
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 30, 2026, 4:14 AM EDT
Not listed Not applicable Interventional

Using Virtual Reality for Patients With Gastrointestinal Disease

NCT03719209
View directory record Official record
Conditions
Gastrointestinal Disease, Inflammatory Bowel Diseases
Interventions
HealthVoyager, Standard Practice
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Antibody Treatment for Advanced Celiac Disease

NCT01893775
View directory record Official record
Conditions
Celiac Disease, Celiac Sprue, Gluten Enteropathy, Gluten-Sensitive Enteropathy
Interventions
Hu-Mik- Beta-1
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Sep 30, 2026, 4:14 AM EDT
Completed No phase listed Observational

Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin

NCT01558570
View directory record Official record
Conditions
Schizophrenia, Celiac Disease
Interventions
Blood Draw
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 30, 2026, 4:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis (EUS-CPN) for Chronic Pancreatitis

NCT04403074
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Celiac Plexus Neurolysis
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

NCT05574010
View directory record Official record
Conditions
Celiac Disease
Interventions
Cohort 1 in Part A, Cohort 2 in Part A, Placebo: Group 1 in Part B and Part C, Group 2 in Part B and Part C, Group 3 in Part B and Part C, Group 4 in Part B and Part C
Drug · Other
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Anaheim, California • St. Petersburg, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

NCT00669825
View directory record Official record
Conditions
Celiac Disease
Interventions
ALV003, Placebo
Drug
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available

Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study

NCT00578279
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dehydrated alcohol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

NCT01094041
View directory record Official record
Conditions
Diarrhea, Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Gluten free diet, Gluten rich diet
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Sep 30, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

NCT04243551
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug · Other
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis

NCT03152487
View directory record Official record
Conditions
Pancreatic Carcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer, Pancreatic Cancer, Adult
Interventions
Celiac Plexus Neurolysis, Radiofrequency Ablation
Other
Lead sponsor
AdventHealth
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Celiac Plexus Radio-Surgery for Pain Management

NCT03323489
View directory record Official record
Conditions
Advanced Cancer, Pancreas Cancer, Pain
Interventions
Celiac Plexus Radiosurgery
Radiation
Lead sponsor
Dr. Yaacov Lawrence
Government
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

Evaluate the Use of Optical Frequency Domain Imaging (OFDI) for Celiac Disease in Children, Adolescents and Young Adults

NCT01439035
View directory record Official record
Conditions
Celiac Disease
Interventions
MGH OFDI Imaging
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 30, 2026, 4:14 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule

NCT02202681
View directory record Official record
Conditions
Celiac Disease, Healthy
Interventions
OFDI Capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 30, 2026, 4:14 AM EDT